| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 01/30/2003 | US20030022907 Anxiolytic agents and analgesics |
| 01/30/2003 | US20030022901 Serotonergic agents |
| 01/30/2003 | US20030022900 Compositions comprising alpha-1C specific compounds |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022865 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 01/30/2003 | US20030022852 Biodegradable immunomodulatory formulations and methods for use thereof |
| 01/30/2003 | US20030022836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 01/30/2003 | US20030022338 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 01/30/2003 | US20030022284 Polypeptide for use in the diagnosis and treatment of kidney defects |
| 01/30/2003 | US20030022275 Human nk-3 related prostate specific gene-1 |
| 01/30/2003 | US20030021854 Nanocrystal microbiocide metal |
| 01/30/2003 | US20030021792 Quantitative analysis; immunosuppressants, anticoagulants |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453636A1 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | CA2453613A1 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | CA2453602A1 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | CA2453294A1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/30/2003 | CA2417955A1 Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 01/29/2003 | EP1279666A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/29/2003 | EP1279404A1 Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| 01/29/2003 | EP1278893A2 Diagnosis of diseases associated with dna replication |
| 01/29/2003 | EP1278869A2 Proteases |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278838A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278778A2 Modified peptides, comprising an fc domain, as therapeutic agents |
| 01/29/2003 | EP1278774A2 Human g-protein coupled receptors |
| 01/29/2003 | EP1278770A1 Human wingless-like gene |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278749A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/29/2003 | EP1278748A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 01/29/2003 | EP1278747A1 Pyrano, piperidino, and thiopyrano compounds and methods of use |
| 01/29/2003 | EP1278746A2 Dihydropyridine compounds and methods of use |
| 01/29/2003 | EP1278734A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
| 01/29/2003 | EP1278729A1 Benzosuberonylpiperidine compounds as analgesics |
| 01/29/2003 | EP1278722A1 Aryl and heteroaryl sulfonates |
| 01/29/2003 | EP1278719A1 Naphthamide neurokinin antagonists for use as medicaments |
| 01/29/2003 | EP1278716A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists |
| 01/29/2003 | EP1278547A2 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP0984966B1 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS |
| 01/29/2003 | EP0889884B1 1,2,4-triazine derivatives for the inhibition of protein glycosylation |
| 01/29/2003 | EP0572560B1 Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 01/29/2003 | CN1394206A Novel vitamin D analogues |
| 01/29/2003 | CN1394201A Substituted glutarimides and use thereof IL-12 production inhibitors |
| 01/29/2003 | CN1393263A Health-care food for improving prostatoplasia |
| 01/29/2003 | CN1393229A Medicine for treating prostatic hyperplasia and internal pile and its preparing process |
| 01/29/2003 | CN1099884C Chinese patent medicine for treating nephrosis |
| 01/29/2003 | CN1099871C Shuanggan injecta and preparing method thereof |
| 01/28/2003 | WO2002018372A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
| 01/28/2003 | US6512096 Prostate cell surface antigen-specific antibodies |
| 01/28/2003 | US6511981 Benzyl isooxazole and benzyl pyrazole derivatives as aldose reductase and cyclooxygenase-2 inhibitors |
| 01/28/2003 | CA2148839C Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 01/28/2003 | CA2127553C Peptides with organo-protective activity, process for their preparation and their use in the therapy |
| 01/28/2003 | CA2094300C Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006460A1 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006027A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 01/23/2003 | WO2003006019A1 Medicinal composition for treatment of interstitial cystitis |
| 01/23/2003 | WO2003005964A2 Recombinant vsv for the treatment of tumor cells |
| 01/23/2003 | WO2002083159B1 Palliative effects of morinda citrifolia oil and juice |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |
| 01/23/2003 | WO2002066978A3 Detection of compounds that modulate inflammatory responses |
| 01/23/2003 | WO2002066475A3 Tricyclic androgen receptor modulator compounds |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002041835A3 Estrogen receptor modulators |
| 01/23/2003 | WO2002038133A3 Compositions containing hydrolytically unstable compounds |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2001089548A3 Pharmaceutical use of fibulin-1 |
| 01/23/2003 | WO2001005805A9 Novel c-19-halogen-substituted, 5-substituted, 5-substituted or 6,10 carbocyclically condensed steroids of the androst-9(11)-ene-series, methods for the production and use thereof |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018083 Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018066 Administering vitamin e and selenium, or compound thereof |
| 01/23/2003 | US20030018061 Novel remedies with the use of beta 3 agonist |
| 01/23/2003 | US20030018060 Therapeutic methods and compositions involving isoflavones |
| 01/23/2003 | US20030018053 Substituted indolealkanoic acids |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030018040 Tumor necrosis factor antagonist; side effect reduction;antiinflammatory agents |
| 01/23/2003 | US20030018024 Biphenyl vasopressin agonists |
| 01/23/2003 | US20030018021 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists |
| 01/23/2003 | US20030018013 Cardiovascular disorders; antilipemic agents; Alzheimer's disease |
| 01/23/2003 | US20030017988 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 01/23/2003 | US20030017977 Methods of treating inflammatory skin diseases |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017157 Endothelial cell expression patterns |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | CA2707767A1 Biologically active peptides |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2452517A1 Recombinant vsv for the treatment of tumor cells |